Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition

Clinical Infectious Diseases

Volumn 54, Issue 6, 2012, Pages 853-861

  Cingolani, Antonella ^a   Lepri, Alessandro Cozzi ^g,h   Castagna, Antonella ^c   Goletti, Delia ^b   De Luca, Andrea ^e   Scarpellini, Paolo ^c   Fanti, Iuri ^a,f   Antinori, Andrea ^b   Monforte, Antonella D'Arminio ^d,f   Girardi, Enrico ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Siena University Hospital   (Italy)

^f Icona Foundation Study   (Italy)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TUBERCULOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 84857591080     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir900     Document Type: Article

References (40)

1. 2008 Report on the global AIDS epidemic: update.geneva: Joint United Nations Programme on HIV/AIDS, UNAIDS/WHO, 2008.
2. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-91.
3. Meya DB, McAdam KP. The TB pandemic: an old problem seeking new solutions. J Intern med 2007; 261: 309-29. (Pubitemid 46474764)
4. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIVassociated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190: 1670-6. (Pubitemid 39411018)
5. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 42-6. (Pubitemid 44306486)
6. Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-82. (Pubitemid 41759864)
7. Mussini C, Manzardo C, Johnson M, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22: 2461-9.
8. Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Med 2010; 12: 61-4.
9. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD41 T-cell changes independent of viral load. Blood 2004; 104: 942-7. (Pubitemid 39038012)
10. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15: 1749-56. (Pubitemid 32939234)
11. Brenchley JM, Price DA, Schacker TW. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71. (Pubitemid 44924494)
12. Siddique MA, Hartman KE, Dragileva E, et al. Low CD41 T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis 2006; 194: 661-5. (Pubitemid 44297852)
13. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003; 33: 125-33. (Pubitemid 36793144)
14. Benito JM, López M, Lozano S, et al. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD41 T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38: 373-81. (Pubitemid 40381546)
15. Merlini E, Bai F, Bellistrì GM, Tincati C, d'Arminio Monforte A, Marchetti G. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 2011; 6: e18580.
16. Bai F, Bellistrì GM, Tincati C, et al. Reduced CD127 expression on peripheral CD41 T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. AIDS 2010; 24: 2590-3.
17. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006; 20: 1171-9. (Pubitemid 43786106)
18. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naïve HIV-infected individuals. Clin Infect Dis 2005; 40: e101-9.
19. Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLos One 2010; 5: e10527.
20. Elsherbiny D, Ren Y, McIlleron H, Maartens G, Simonsson US. Population pharmacokinetics of lopinavir in combination with rifampicinbased antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol 2010; 66: 1017-23.
21. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institute of Health and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58(RR-4): 1-207.
22. Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995; 51: 1469-82. (Pubitemid 26030191)
23. Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198: 1590-8.
24. Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009; 180: 1262-70.
25. Jambo KC, Sepako E, Fullerton DG, et al. Bronchoalveolar CD41T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax 2011; 66: 375-82.
26. Geldmacher C, Ngwenyama N, Schuetz A, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 2010; 207: 2869-81.
27. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157: 1271-8. (Pubitemid 126449644)
28. Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. J Infect Dis 1998; 177: 1332-8. (Pubitemid 28194275)
29. Kastenbauer U, Wolf E, Kollan C, Hamouda O, Bogner JR. ClinSurv Study Group. Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease. Eur J Med Res 2009; 14: 244-9.
30. Lazaro E, Coureau G, Guedj J, et al. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir Ther 2006; 11: 343-50. (Pubitemid 43823553)
31. Dronda F, Sobrino P, Hernandez-Novoa B, et al. Response to HAART in treatment-naïve HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections. Curr HIV Res 2011; (Epub ahead of print).
32. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD41 T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-43. (Pubitemid 36578959)
33. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS 1998; 12: 2115-23. (Pubitemid 28495265)
34. Hertoghe T, Wajja A, Ntambi L, et al. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol 2000; 122: 350-7. (Pubitemid 32002192)
35. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188: 1146-55. (Pubitemid 37338979)
36. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-12. (Pubitemid 44162402)
37. Lancioni CL, Mahan CS, Johnson DF, et al. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD41 .350 cells/mm3. J Infect Dis 2011; 203: 992-1001.
38. Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART. AIDS 2011; 25: 49-55.
39. Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199: 437-4.
40. Lawn SD, Bekker LG,Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-73. (Pubitemid 40779257)